Royalty Pharma Aims to Buy Elan for $6.5 Billion

RP Management LLC, an investor in royalty streams from pharmaceuticals, offered to buy Elan Corp. for about $6.5 billion, threatening the Irish drugmaker’s plan to embark on its own acquisitions. Read the full story here.